AI Engines For more Details: Perplexity Kagi Labs You
Gastroesophageal Reflux Disease (GERD): Rabeprazole is highly effective in treating GERD, a condition characterized by the backward flow of stomach acid into the esophagus, causing symptoms such as heartburn, regurgitation, and chest pain.
Peptic Ulcers: Rabeprazole is used to treat peptic ulcers, including gastric ulcers (in the stomach) and duodenal ulcers (in the upper part of the small intestine). It helps promote ulcer healing and prevents their recurrence by reducing stomach acid production.
Helicobacter pylori Eradication: Rabeprazole is often prescribed as part of a combination therapy to eradicate Helicobacter pylori bacteria, which can contribute to the development of ulcers and gastritis.
Gastritis: Rabeprazole can help alleviate the symptoms of gastritis, an inflammation of the stomach lining often caused by excessive stomach acid production or Helicobacter pylori infection.
Zollinger-Ellison Syndrome: This rare condition is characterized by the overproduction of stomach acid, leading to severe ulcers in the stomach and small intestine. Rabeprazole is used to manage symptoms and reduce acid secretion in patients with Zollinger-Ellison syndrome.
Non-Ulcer Dyspepsia: Rabeprazole may be prescribed to alleviate symptoms of non-ulcer dyspepsia, including upper abdominal pain, bloating, and discomfort, particularly when these symptoms are related to excess stomach acid.
Prevention of NSAID-Induced Ulcers: Nonsteroidal anti-inflammatory drugs (NSAIDs) can cause gastrointestinal ulcers and bleeding. Rabeprazole is sometimes prescribed to individuals taking NSAIDs long-term to reduce the risk of ulcers and associated complications.
Reflux Esophagitis: Rabeprazole is effective in treating reflux esophagitis, a condition characterized by inflammation and damage to the esophagus due to repeated exposure to stomach acid.
Barrett's Esophagus: Rabeprazole may be used as part of the treatment plan for Barrett's esophagus, a complication of GERD characterized by changes in the lining of the esophagus that may increase the risk of esophageal cancer.
Eosinophilic Esophagitis: In some cases, rabeprazole may be prescribed as part of the management of eosinophilic esophagitis, an allergic inflammatory condition of the esophagus that can cause difficulty swallowing and other symptoms.
| Rank | Probiotic | Impact |
|---|---|---|
| genus | Bifidobacterium | Reduces |
| species | Bacteroides uniformis | Reduces |
| species | Bifidobacterium adolescentis | Reduces |
| species | Escherichia coli | Reduces |
| species | Lacticaseibacillus paracasei | Reduces |
| species | Parabacteroides distasonis | Reduces |
We extend modifiers to include items that changes the parent and child taxa. I.e. for a species, that would be the genus that is belongs to and the strains in the species.
A higher number indicates impact on more bacteria associated with the condition and confidence on the impact.
We have X bacteria high and Y low reported. We find that the modifier reduces some and increases other of these two groups. We just tally: X|reduces + Y|Increase = Positive X|increases + Y|decrease = Negative.
Benefit Ratio:
Numbers above 0 have increasing positive effect.
Numbers below 0 have increasing negative effect.
| Condition | Positive Impact | Negative Impact | Benefit Ratio Impact |
|---|---|---|---|
| Abdominal Aortic Aneurysm | 0.8 | 0.8 | |
| Acne | 0.3 | -0.3 | |
| ADHD | 2.7 | 0.3 | 8 |
| Age-Related Macular Degeneration and Glaucoma | 1.1 | 0.4 | 1.75 |
| Allergic Rhinitis (Hay Fever) | 3.9 | 1.9 | 1.05 |
| Allergies | 5.1 | 2.4 | 1.13 |
| Allergy to milk products | 2 | 1.6 | 0.25 |
| Alopecia (Hair Loss) | 1.6 | 1.6 | |
| Alzheimer's disease | 5.5 | 6.5 | -0.18 |
| Amyotrophic lateral sclerosis (ALS) Motor Neuron | 3 | 0.9 | 2.33 |
| Ankylosing spondylitis | 4.3 | 1.8 | 1.39 |
| Anorexia Nervosa | 1.6 | 2.9 | -0.81 |
| Antiphospholipid syndrome (APS) | 1.5 | 0.3 | 4 |
| Asthma | 5.2 | 1.5 | 2.47 |
| Atherosclerosis | 3.2 | 1.3 | 1.46 |
| Atrial fibrillation | 3.8 | 2.8 | 0.36 |
| Autism | 9.2 | 9 | 0.02 |
| Autoimmune Disease | 1.2 | 1 | 0.2 |
| Barrett esophagus cancer | 0.3 | 0.3 | 0 |
| benign prostatic hyperplasia | 0.6 | 0.3 | 1 |
| Biofilm | 3.2 | 3.2 | |
| Bipolar Disorder | 2.1 | 1.1 | 0.91 |
| Brain Trauma | 0.9 | 1.4 | -0.56 |
| Breast Cancer | 1.2 | 1.2 | |
| Cancer (General) | 0.3 | 1.1 | -2.67 |
| Carcinoma | 4.4 | 2.3 | 0.91 |
| Celiac Disease | 3.5 | 2.6 | 0.35 |
| Cerebral Palsy | 1.1 | 1.3 | -0.18 |
| Chronic Fatigue Syndrome | 4.1 | 6.9 | -0.68 |
| Chronic Kidney Disease | 3.4 | 2.9 | 0.17 |
| Chronic Lyme | 0.8 | -0.8 | |
| Chronic Obstructive Pulmonary Disease (COPD) | 3.2 | 1.7 | 0.88 |
| Chronic Urticaria (Hives) | 1.7 | 0.9 | 0.89 |
| Coagulation / Micro clot triggering bacteria | 1.9 | 1.3 | 0.46 |
| Cognitive Function | 3.1 | 1.3 | 1.38 |
| Colorectal Cancer | 7.1 | 2.8 | 1.54 |
| Constipation | 2.1 | 0.7 | 2 |
| Coronary artery disease | 3 | 2.5 | 0.2 |
| COVID-19 | 7.7 | 9.6 | -0.25 |
| Crohn's Disease | 9.1 | 6.1 | 0.49 |
| Cushing's Syndrome (hypercortisolism) | 1 | -1 | |
| cystic fibrosis | 1.7 | 1.3 | 0.31 |
| d-lactic acidosis (one form of brain fog) | 0.6 | 0.6 | |
| deep vein thrombosis | 2.7 | 1.4 | 0.93 |
| Denture Wearers Oral Shifts | 1.5 | 1.5 | |
| Depression | 9.6 | 8.5 | 0.13 |
| Dermatomyositis | 0.3 | 0.3 | 0 |
| Eczema | 2.5 | 1.6 | 0.56 |
| Endometriosis | 3.5 | 2 | 0.75 |
| Eosinophilic Esophagitis | 0.3 | 0.3 | 0 |
| Epilepsy | 4 | 1.7 | 1.35 |
| erectile dysfunction | 1.4 | 0.3 | 3.67 |
| Fibromyalgia | 2.9 | 1.9 | 0.53 |
| Functional constipation / chronic idiopathic constipation | 5.4 | 4 | 0.35 |
| gallstone disease (gsd) | 4 | 1.1 | 2.64 |
| Gastroesophageal reflux disease (Gerd) including Barrett's esophagus | 2.7 | 1.2 | 1.25 |
| Generalized anxiety disorder | 3.1 | 1.4 | 1.21 |
| giant cell arteritis | 0.2 | -0.2 | |
| Glioblastoma | 0.3 | -0.3 | |
| Gout | 0.9 | 0.5 | 0.8 |
| Graves' disease | 1.6 | 3 | -0.88 |
| Gulf War Syndrome | 0.9 | 0.9 | 0 |
| Halitosis | 1.5 | 0.3 | 4 |
| Hashimoto's thyroiditis | 3.6 | 1.8 | 1 |
| Heart Failure | 5.4 | 1.9 | 1.84 |
| hemorrhagic stroke | 1.3 | 1.3 | |
| Hidradenitis Suppurativa | 1.4 | 1.4 | |
| High Histamine/low DAO | 1.9 | 0.6 | 2.17 |
| hypercholesterolemia (High Cholesterol) | 0.8 | 0.8 | |
| hyperglycemia | 1.3 | 1.1 | 0.18 |
| Hyperlipidemia (High Blood Fats) | 0.9 | 0.3 | 2 |
| hypersomnia | 0.7 | -0.7 | |
| hypertension (High Blood Pressure | 4.7 | 3.8 | 0.24 |
| Hypothyroidism | 0.7 | -0.7 | |
| Hypoxia | 3.6 | 0.3 | 11 |
| IgA nephropathy (IgAN) | 1.6 | 2.8 | -0.75 |
| Inflammatory Bowel Disease | 6.6 | 8.9 | -0.35 |
| Insomnia | 1.7 | 2.6 | -0.53 |
| Intelligence | 1.5 | 0.3 | 4 |
| Intracranial aneurysms | 1.4 | 0.6 | 1.33 |
| Irritable Bowel Syndrome | 6.6 | 4 | 0.65 |
| ischemic stroke | 2.3 | 1.7 | 0.35 |
| Juvenile idiopathic arthritis | 0.5 | 0.5 | |
| Liver Cirrhosis | 6.1 | 4 | 0.52 |
| Long COVID | 5.5 | 6.7 | -0.22 |
| Low bone mineral density | 1.1 | -1.1 | |
| Lung Cancer | 0.9 | 1 | -0.11 |
| Lymphoma | 0.6 | 0.6 | |
| Mast Cell Issues / mastitis | 1.5 | 0.9 | 0.67 |
| ME/CFS with IBS | 0.8 | 2.4 | -2 |
| ME/CFS without IBS | 1.1 | 2.4 | -1.18 |
| membranous nephropathy | 0.3 | 0.3 | |
| Menopause | 0.4 | 0.5 | -0.25 |
| Metabolic Syndrome | 7.6 | 5.4 | 0.41 |
| Mood Disorders | 7.8 | 7.3 | 0.07 |
| multiple chemical sensitivity [MCS] | 0.4 | 0.1 | 3 |
| Multiple Sclerosis | 6.3 | 6.8 | -0.08 |
| Multiple system atrophy (MSA) | 0.6 | 0.7 | -0.17 |
| myasthenia gravis | 0.9 | 0.7 | 0.29 |
| neuropathic pain | 1.6 | -1.6 | |
| Neuropathy (all types) | 0.4 | 1.6 | -3 |
| neuropsychiatric disorders (PANDAS, PANS) | 0.9 | 0.9 | |
| Nonalcoholic Fatty Liver Disease (nafld) Nonalcoholic | 4.9 | 3.9 | 0.26 |
| NonCeliac Gluten Sensitivity | 1 | 0.6 | 0.67 |
| Obesity | 8.3 | 6.6 | 0.26 |
| obsessive-compulsive disorder | 5.1 | 3.7 | 0.38 |
| Osteoarthritis | 2.4 | 1.2 | 1 |
| Osteoporosis | 1.9 | 1.3 | 0.46 |
| pancreatic cancer | 0.9 | 0.3 | 2 |
| Parkinson's Disease | 7.5 | 6.7 | 0.12 |
| Polycystic ovary syndrome | 7.9 | 2.9 | 1.72 |
| Postural orthostatic tachycardia syndrome | 0.2 | 0.6 | -2 |
| Premenstrual dysphoric disorder | 0.7 | 0.4 | 0.75 |
| primary biliary cholangitis | 0.9 | 1.2 | -0.33 |
| Primary sclerosing cholangitis | 2.1 | 3.2 | -0.52 |
| Psoriasis | 3.9 | 3.1 | 0.26 |
| rheumatoid arthritis (RA),Spondyloarthritis (SpA) | 8.3 | 4.1 | 1.02 |
| Rosacea | 1.2 | 0.7 | 0.71 |
| Schizophrenia | 5.2 | 2.8 | 0.86 |
| scoliosis | 0.9 | 1.3 | -0.44 |
| Sjögren syndrome | 1.8 | 2.2 | -0.22 |
| Sleep Apnea | 2.2 | 1.6 | 0.38 |
| Slow gastric motility / Gastroparesis | 1.2 | 0.3 | 3 |
| Small Intestinal Bacterial Overgrowth (SIBO) | 2 | 2 | |
| Stress / posttraumatic stress disorder | 3.2 | 2.1 | 0.52 |
| Systemic Lupus Erythematosus | 4.5 | 1.6 | 1.81 |
| Tic Disorder | 1.3 | 1.5 | -0.15 |
| Tourette syndrome | 0.9 | 0.3 | 2 |
| Type 1 Diabetes | 4.2 | 3 | 0.4 |
| Type 2 Diabetes | 8.4 | 5.8 | 0.45 |
| Ulcerative colitis | 6.3 | 4.4 | 0.43 |
| Unhealthy Ageing | 5.4 | 2.2 | 1.45 |
| Vitiligo | 2.5 | 1.5 | 0.67 |
